America's Most Hated CEOs

[anonymous]

Leadership (I sorta throw up a little in my mouth when I say that word) should be buying shire stock if they have such confidence in the transition of shire to a true biotech. But they don't which goes to show how much they think shire will perform.

Clearly you have no understanding of company financials. Shire was absolutely correct to focus on debt reduction after the Baxalta buyout. With net debt to ebitda set to drop below 3, in 2018 Shire will be in a much stronger position to allocate capital to share buybacks, and I expect that to happen if the share price stays depressed for much longer.